With the majority of colorectal cancer patients displaying “immunologically cold” tumours and poor response to ICIs (99), this represents an exciting therapeutic angle: turning “cold” tumours “hot” through increased recruitment of CD8+ T cells provides a platform to increase efficacy of ICIs in the context of cancers which have traditionally shown limited response such as colorectal carcinoma and PDAC. The gene discussed is CD8A; the disease is cancer.